We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    covalent-102
Previous Study | Return to List | Next Study

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05631574
Recruitment Status : Recruiting
First Posted : November 30, 2022
Last Update Posted : May 3, 2023
Sponsor:
Information provided by (Responsible Party):
Biomea Fusion Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Pancreatic Cancer Colorectal Cancer NSCLC PDAC CRC Relapsed Cancer Refractory Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Stage III Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Stage III Colorectal Cancer Stage IV Colorectal Cancer Stage III NSCLC Stage IV NSCLC KRAS Mutation-Related Tumors Drug: BMF-219 Phase 1

Detailed Description:
This is a dose finding study to determine the safety and tolerability, pharmacokinetics and pharmacodynamics, and clinical activity of escalating doses of BMF-219 administered orally (PO) either once daily (QD) or twice daily (BID) in 28-day cycles. After observing acceptable safety performance in these dosing regimens, additional subjects will be enrolled to assess efficacy in the determination of the OBD for use as a RP2D.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: This study is an ascending multiple dose clinical trial followed by cohort expansion. The dose escalation part is primarily intended to identify the optimal biologic dose (OBD)(s) of BMF-219 and to obtain initial safety and tolerability information regarding the compound when administered orally to subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. This study will also evaluate the PK/PD profiles of multiple dose administration of BMF-219. Following completion of the dose escalation, cohort and arm-specific expansion cohorts will commence in order to further confirm the safety and tolerability of BMF-219 dosed at or near the OBD.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)
Actual Study Start Date : January 12, 2023
Estimated Primary Completion Date : June 2025
Estimated Study Completion Date : October 2026

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Escalation Phase

Dose Escalation Phase will group all disease indications (NSCLC, PDAC, and CRC) together to assess the safety of each dose level.

Participants will receive escalating dose BMF-219 orally once per day or twice per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).

 Drug: BMF-219
BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Experimental: Expansion Phase

Dose Expansion Phase will enroll additional subjects independently in each disease indication:

Cohort 1: Participants with NSCLC

Cohort 2: Participants with PDAC

Cohort 3: Patients with CRC

Cohorts 1, 2, and 3 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug.

 Drug: BMF-219
BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. [ Time Frame: 30 months ]
    OBD/RP2D as determined by the number of subjects receiving BMF-219 monotherapy who experience Dose-Limiting Toxicities (DLTs) within each dose level. A DLT is defined as any clinically significant Adverse Event within 28 days of starting BMF-219 treatment and considered to be related to the IMP. Adverse Events will be assessed per CTCAE v5.0.

  2. To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. [ Time Frame: 30 months ]
    OBD/RP2D as measured by objective response rate (ORR). ORR will be assessed using RECIST 1.1 per investigator assessment.


Secondary Outcome Measures :
  1. To evaluate the safety and tolerability of BMF-219 monotherapy. [ Time Frame: 46 months ]
    Safety and tolerability will be determined using treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) as outcomes.

  2. To evaluate the pharmacokinetics of BMF-219. [ Time Frame: 46 months ]
    Pharmacokinetics will be determined using maximum observed plasma concentration (Cmax ).

  3. To evaluate the pharmacokinetics of BMF-219. [ Time Frame: 46 months ]
    Pharmacokinetics will be determined time to maximum plasma concentration (tmax).

  4. To evaluate the pharmacokinetics of BMF-219. [ Time Frame: 46 months ]
    Pharmacokinetics will be determined using the AUC from time 0 to last quantifiable concentration (AUClast ).

  5. To evaluate the efficacy of BMF-219 monotherapy in subjects with unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. [ Time Frame: 46 months ]
    Efficacy will be determined using duration of response (DOR), defined by the duration of time from the date of initial response of PR or better to the date of disease progression or death due to any cause, whichever occurs first. DOR will be assessed using RECIST 1.1 per investigator assessment.

  6. To evaluate the efficacy of BMF-219 monotherapy in subjects with unresectable, locally advanced, or metastatic NSCLC, PDAC and CRC. [ Time Frame: 46 months ]
    Efficacy determined by disease control rate (DCR), defined as the proportion of response-evaluable subjects who maintain disease control (Complete Response, Partial Response or SD as per RECIST 1.1) from first dose through Week 6.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Adults with a confirmed diagnosis of unresectable, locally advanced and/or metastatic Stage IIIB/IV NSCLC, Stage III/IV PDAC and/or Stage III/IV CRC with no curative-intent treatment options and documented activating KRAS mutation (without known additional actionable driver mutations such as EGFR, ALK or ROS1)

  2. Documented progression and measurable disease after ≥ 1 prior line of systemic therapy (≥ 2 and

    ≤ 4 prior lines for NSCLC) with adequate washout period and resolution of treatment-related toxicities to ≤ Grade 2

  3. ECOG PS of 0-2 (0-1 for PDAC) and a life expectancy > 3 months in the opinion of the Investigator
  4. Adequate hematological, liver, and renal function
  5. Men and women of childbearing potential must use adequate birth control measures for the duration of the trial and at least 90 days after discontinuing study treatment

Exclusion Criteria

  1. Symptomatic and/or untreated CNS or brain metastasis, pre-existing ILD or pericardial/pleural effusion of ≥ grade 2 or requiring chronic oxygen therapy for COPD or pleural effusions
  2. Serious concomitant disorder including infection
  3. Known positive test for HIV, HCV, HBV surface antigen
  4. Concurrent malignancy in the previous 2 years
  5. Prior menin inhibitor therapy
  6. Requiring treatment with a strong or moderate CYP3A inhibitor/inducer
  7. Significant cardiovascular disease or QTcF or QTcB prolongation.
  8. Major surgery within 4 weeks prior to first dose
  9. Women who are pregnant or lactating.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05631574


Contacts
Layout table for location contacts
Contact: Alex Cacovean, MD 1-844-245-0490 clinicaltrials@biomeafusion.com
Contact: Tracy Tong 1-844-245-0490 clinicaltrials@biomeafusion.com

Locations
Show Show 18 study locations
Sponsors and Collaborators
Biomea Fusion Inc.
Investigators
Layout table for investigator information
Study Director: Stephan Morris, MD Biomea Fusion Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Biomea Fusion Inc.
ClinicalTrials.gov Identifier: NCT05631574    
Other Study ID Numbers: COVALENT-102
First Posted: November 30, 2022    Key Record Dates
Last Update Posted: May 3, 2023
Last Verified: April 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Biomea Fusion Inc.:
Oral Covalent Menin Inhibitor
Relapsed
Refractory
Irreversible Menin Inhibitor
Menin Inhibitor
Unresectable
 Locally Advanced
Metastatic
Menin
Menin Therapy
KRAS
KRAS Mutated
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Pancreatic Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
 Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases